Barriers of linkage to HCV viremia testing among people who inject drugs in Georgia

被引:3
作者
Butsashvili, Maia [1 ,2 ]
Abzianidze, Tinatin [1 ,2 ]
Kamkamidze, George [1 ]
Gulbiani, Lasha [1 ]
Gvinjilia, Lia [3 ]
Kuchuloria, Tinatin [3 ]
Tskhomelidze, Irina [3 ]
Gogia, Maka [4 ]
Tsereteli, Maia [5 ]
Miollany, Veronique [6 ]
Kikvidze, Tamar [6 ]
Shadaker, Shaun [7 ]
Nasrullah, Muazzam [7 ]
Averhoff, Francisco [7 ]
机构
[1] Hlth Res Union Clin NEOLAB, 8 Nutsubidze Str, GE-0177 Tbilisi, Georgia
[2] Univ Georgia, 77a MKostava Str, GE-0171 Tbilisi, Georgia
[3] TEPHINET, 9 Asatiani St, GE-0177 Tbilisi, Georgia
[4] Georgian Harm Reduct Network, 24 Shartava Str 3rd Floor,Apt 6, Tbilisi, Georgia
[5] Natl Ctr Dis Control & Publ Hlth, 99 Kakheti Highway, GE-0198 Tbilisi, Georgia
[6] Medecins Monde, 24 Paliashvili Str, GE-0179 Tbilisi, Georgia
[7] CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd, Atlanta, GA 30329 USA
关键词
PWID; Diagnosis; HCV; Elimination; Barriers; HEPATITIS-C VIRUS; UNDERSTANDING BARRIERS; ELIMINATION PROGRAM; CARE; INFECTION; MODELS;
D O I
10.1186/s13011-022-00438-6
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background People who inject drugs (PWID) in Georgia have a high prevalence of hepatitis C virus antibody (anti-HCV). Access to care among PWID could be prioritized to meet the country's hepatitis C elimination goals. This study assesses barriers of linkage to HCV viremia testing among PWID in Georgia. Methods Study participants were enrolled from 13 harm reduction (HR) centers throughout Georgia. Anti-HCV positive PWID who were tested for viremia (complete diagnosis [CD]), were compared to those not tested for viremia within 90 days of screening anti-HCV positive (not complete diagnosis [NCD]). Convenience samples of CD and NCD individuals recorded at HR centers using beneficiaries' national ID were drawn from the National HCV Elimination Program database. Participants were interviewed about potential barriers to seeking care. Results A total of 500 PWID were enrolled, 245 CD and 255 NCD. CD and NCD were similar with respect to gender, age, employment status, education, knowledge of anti-HCV status, and confidence/trust in the elimination program (p > 0.05). More NCD (13.0%) than CD (7.4%) stated they were not sufficiently informed what to do after screening anti-HCV positive (p < 0.05). In multivariate analysis, HCV viremia testing was associated with perceived affordability of the elimination program (adjusted prevalence ratio = 8.53; 95% confidence interval: 4.14-17.62). Conclusions Post testing counselling and making hepatitis C services affordable could help increase HCV viremia testing among PWID in Georgia.
引用
收藏
页数:6
相关论文
共 24 条
[1]   Excellence in viral hepatitis elimination - Lessons from Georgia [J].
Averhoff, Francisco ;
Lazarus, Jeffrey V. ;
Sergeenko, David ;
Colombo, Massimo ;
Gamkrelidze, Amiran ;
Tsertsvadze, Tengiz ;
Butsashvili, Maia ;
Metreveli, David ;
Sharvadze, Lali ;
Hellard, Margaret ;
Gnes, Stefano ;
Gabunia, Tamar ;
Nasrullah, Muazzam .
JOURNAL OF HEPATOLOGY, 2019, 71 (04) :645-647
[2]   Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review [J].
Bajis, Sahar ;
Dore, Gregory J. ;
Hajarizadeh, Behzad ;
Cunningham, Evan B. ;
Maher, Lisa ;
Grebely, Jason .
INTERNATIONAL JOURNAL OF DRUG POLICY, 2017, 47 :34-46
[3]   Direct acting antiviral-based treatment of hepatitis C virus infection among people who inject drugs in Georgia: A prospective cohort study [J].
Bouscaillou, Julie ;
Kikvidze, Tamar ;
Butsashvili, Maia ;
Labartkava, Konstantine ;
Inaridze, Ina ;
Etienne, Aurelie ;
Le Pluart, Diane ;
Kamkamidze, George ;
Gamezardashvili, Ana ;
Kharshiladze, David ;
Avril, Elisabeth ;
Luhmann, Nildas .
INTERNATIONAL JOURNAL OF DRUG POLICY, 2018, 62 :104-111
[4]   Hepatitis C among people who inject drugs in Tbilisi, Georgia: An urgent need for prevention and treatment [J].
Bouscaillou, Julie ;
Champagnat, Julie ;
Luhmann, Niklas ;
Avril, Elisabeth ;
Inaridze, Ina ;
Miollany, Veronique ;
Labartkava, Koka ;
Kirtadze, Irma ;
Butsashvili, Maia ;
Kamkamidze, George ;
Pataut, Dominique .
INTERNATIONAL JOURNAL OF DRUG POLICY, 2014, 25 (05) :871-878
[5]   Models of Care for the Management of Hepatitis C Virus Among People Who Inject Drugs: One Size Does Not Fit All [J].
Bruggmann, Philip ;
Litwin, Alain H. .
CLINICAL INFECTIOUS DISEASES, 2013, 57 :S56-S61
[6]  
Chihota V., 2018, APPROACHES PROVIDING
[7]   On the way to Hepatitis C elimination in the Republic of Georgia-Barriers and facilitators for people who inject drugs for engaging in the treatment program: A formative qualitative study [J].
Chikovani, Ivdity ;
Ompad, Danielle C. ;
Uchaneishvili, Maia ;
Sulaberidze, Lela ;
Sikharulidze, Ketevan ;
Hagan, Holly ;
Van Devanter, Nancy L. .
PLOS ONE, 2019, 14 (04)
[8]   Peer Support Models for People With a History of Injecting Drug Use Undertaking Assessment and Treatment for Hepatitis C Virus Infection [J].
Crawford, Sione ;
Bath, Nicky .
CLINICAL INFECTIOUS DISEASES, 2013, 57 :S75-S79
[9]   Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review [J].
Degenhardt, Louisa ;
Peacock, Amy ;
Colledge, Samantha ;
Leung, Janni ;
Grebely, Jason ;
Vickerman, Peter ;
Stone, Jack ;
Cunningham, Evan B. ;
Trickey, Adam ;
Dumchev, Kostyantyn ;
Lynskey, Michael ;
Griffiths, Paul ;
Mattick, Richard P. ;
Hickman, Matthew ;
Larney, Sarah .
LANCET GLOBAL HEALTH, 2017, 5 (12) :E1192-E1207
[10]   Hepatitis C prevalence and risk factors in Georgia, 2015: setting a baseline for elimination [J].
Hagan, Liesl M. ;
Kasradze, Ana ;
Salyer, Stephanie J. ;
Gamkrelidze, Amiran ;
Alkhazashvili, Maia ;
Chanturia, Gvantsa ;
Chitadze, Nazibrola ;
Sukhiashvili, Roena ;
Shakhnazarova, Marina ;
Russell, Steven ;
Blanton, Curtis ;
Kuchukhidze, Giorgi ;
Baliashvili, Davit ;
Hariri, Susan ;
Ko, Stephen ;
Imnadze, Paata ;
Drobeniuc, Jan ;
Morgan, Juliette ;
Averhoff, Francisco .
BMC PUBLIC HEALTH, 2019, 19 (Suppl 3)